Johnson & Johnson reported a strong fourth quarter and full year 2025, characterized by robust sales growth and significant innovation across its key business segments, particularly in Oncology and MedTech.
Q4 2025 reported sales grew 9.1% to $24.6 Billion, with operational growth of 7.1%.
positiveFull-Year 2025 reported sales grew 6.0% to $94.2 Billion, with operational growth of 5.3%.
positiveQ4 2025 adjusted EPS of $2.46, up 20.6% year-over-year.
positiveFull-Year 2025 adjusted EPS of $10.79, up 8.1% year-over-year.
positiveSignificant innovation including FDA approvals for CAPLYTA and RYBREVANT FASPRO plus LAZCLUZE, landmark data for TECVAYLI plus DARZALEX FASPRO, and acquisition of Halda Therapeutics.
positiveQ4 2025 reported EPS of $2.10 includes a $(0.10) impact due to the acquisition of Halda Therapeutics, affecting comparability.
attentionFull-Year 2025 reported EPS of $11.03 includes a $(0.10) impact due to the acquisition of Halda Therapeutics, affecting comparability.
attentionGrowth in Innovative Medicine was partially offset by an approximate (1,040) basis points impact from STELARA in Immunology.
attentionMargin metrics will be available once backend extracts data from insights_json
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Innovative Medicine | $60401000.0B | $56964000.0B | +6.2% | 64.1% | +4.1% |
MedTech | $33792000.0B | $31857000.0B | +4.3% | 35.9% | +4.3% |
| Total Revenue | $94193000.0B | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history.
Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
In each of these important areas, our leadership is expanding driven by game-changing science and technology.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.